Have a feature idea you'd love to see implemented? Let us know!

VERU Veru Inc

Price (delayed)

$0.9104

Market cap

$133.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$108.23M

Veru Inc. is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancer. The Veru prostate cancer pipeline includes VERU-111, ...

Highlights
The EPS has soared by 79% YoY and by 18% from the previous quarter
The net income has soared by 68% YoY and by 3.7% from the previous quarter
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
VERU's gross profit is down by 28% year-on-year but it is up by 2.3% since the previous quarter
The quick ratio has contracted by 26% from the previous quarter
The gross margin has contracted by 23% YoY and by 2.1% from the previous quarter

Key stats

What are the main financial stats of VERU
Market
Shares outstanding
146.38M
Market cap
$133.27M
Enterprise value
$108.23M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.54
Price to sales (P/S)
9.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.68
Earnings
Revenue
$14.09M
EBIT
-$38.65M
EBITDA
-$38.38M
Free cash flow
-$27.12M
Per share
EPS
-$0.33
Free cash flow per share
-$0.19
Book value per share
$0.26
Revenue per share
$0.1
TBVPS
$0.39
Balance sheet
Total assets
$64.63M
Total liabilities
$27.01M
Debt
$4.11M
Equity
$37.62M
Working capital
$27.86M
Liquidity
Debt to equity
0.11
Current ratio
3.62
Quick ratio
2.9
Net debt/EBITDA
0.65
Margins
EBITDA margin
-272.4%
Gross margin
33.4%
Net margin
-284.8%
Operating margin
-281.1%
Efficiency
Return on assets
-60.1%
Return on equity
-104.2%
Return on invested capital
-174.9%
Return on capital employed
-71.6%
Return on sales
-274.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VERU stock price

How has the Veru stock price performed over time
Intraday
9.42%
1 week
20.79%
1 month
4.67%
1 year
14.1%
YTD
26.44%
QTD
18.39%

Financial performance

How have Veru's revenue and profit performed over time
Revenue
$14.09M
Gross profit
$4.71M
Operating income
-$39.61M
Net income
-$40.13M
Gross margin
33.4%
Net margin
-284.8%
The operating income has surged by 70% year-on-year and by 7% since the previous quarter
The net income has soared by 68% YoY and by 3.7% from the previous quarter
The company's operating margin has surged by 68% YoY and by 11% QoQ
VERU's net margin has surged by 66% year-on-year and by 8% since the previous quarter

Growth

What is Veru's growth rate over time

Valuation

What is Veru stock price valuation
P/E
N/A
P/B
3.54
P/S
9.46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.68
The EPS has soared by 79% YoY and by 18% from the previous quarter
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
The P/B is 41% below the 5-year quarterly average of 5.5 but 41% above the last 4 quarters average of 2.3
VERU's price to sales (P/S) is 39% more than its last 4 quarters average of 6.2 but 8% less than its 5-year quarterly average of 9.4
Veru's revenue has decreased by 6% YoY but it has increased by 4.5% QoQ

Efficiency

How efficient is Veru business performance
The return on invested capital has surged by 85% year-on-year and by 9% since the previous quarter
The ROS has soared by 67% YoY and by 7% from the previous quarter
Veru's ROE has soared by 65% YoY and by 14% from the previous quarter
The ROA has soared by 56% YoY and by 4.6% from the previous quarter

Dividends

What is VERU's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VERU.

Financial health

How did Veru financials performed over time
The total assets is 139% more than the total liabilities
Veru's current ratio has soared by 190% YoY but it has decreased by 23% from the previous quarter
The company's total liabilities fell by 34% YoY
VERU's debt is 89% smaller than its equity
The equity has soared by 76% YoY but it has contracted by 17% from the previous quarter
The debt to equity has dropped by 52% year-on-year but it is up by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.